Select your language

Life Sciences & Product Liability Insurers: Have You Anticipated the Transposition of the New Product Liability Directive?

Directive (EU) 2024/2853 of 23 October 2024, which replaces Directive 85/374/EEC, is supposed to be transposed in national Laws by 9 December 2026, and the upcoming changes are significant:

· boarder definition of "product" (eg with express reference to software and digital manufacturing files)
· extension of recoverable damage, notably to medically recognised damage to psychological health and destuction or corruption of certain data
· broader approach to defectiveness taking into account, for example, a product's ability to continue to learn or acquire new features after it's been placed on the market
· extension of the list of potentially liable persons (economic operators)
· changes to the rules of evidence including presumptions of defectiveness and causation and a disclosure of evidence mechanism
· changes to the grounds for exemption from liability and a new time-limit of up to 25 years in cases involving latent personal injury

Potential foreseen consequences in practice :
· more complex claims scenarios (eg self-learning products, Al etc) and more recourse actions between stakeholders
· more technical and potentially longer expert investigations
· higher claims handling costs
·increasingly blurred boundaries between Product liability, Professionnal liabiliaty and Cyber policies, with a risk of overlapping coverage

 

Something to anticipate now, as the transposition is likely to have an impact on policy wording (coordination of coverage, exclusion clauses etc and more broadly on risks and claims management